Biocon Q3 FY25 results (Oct–Dec 2024) and concall

Biocon reported a progressive Q3 FY25 with 10% like-for-like operating revenue growth, driven by strong Biosimilars and Research Services performance. Key regulatory milestones were achieved, including VAI status for major facilities and multiple product approvals, setting the stage for future launches. However, Generics saw a marginal YoY decline and lower reported EBITDA margins due to new facility costs and R&D investments, while group core EBITDA growth was modest.